Fondation MEDIC


Fred Bosman

Prof. Fred T Bosman (chair and MEDIC coordinator)

Emeritus professor of Pathology
University Institute of Pathology
Lausanne University Medical Center (CHUV)

Ferdy Lejeune

Prof. Ferdy Lejeune

Emeritus professor of Oncology
Pluridisciplinary Center of Oncology (CEPO), Lausanne

Marc Mareel

Prof. Marc Mareel

Emeritus professor of Radiation Oncology
Department of Radiation Oncology
University of Ghent, Belgium

Gerhard Christofori

Prof. Gerhard Christofori

Professor of Cell Biology
Institute of Biochemistry and Genetics,
Department of Biomedical Sciences, University of Basel

Holger Moch

Prof. Holger Moch

Professor of Pathology and Director of the Institute
of Surgical Pathology
University of Zürich Medical Center

Prof. Fred Bosman

Biosketch Prof. Fred Bosman

Fred Bosman, (1944, the Netherlands), studied Medicine at the University of Leiden (MD 1971), where he also earned his PhD degree (1976) and trained as a pathologist. He was staff pathologist at the University of Leiden (1975-1981), lecturer at the University of Surinam (1974-1975), Professor and chair of Pathology at the Faculty of Medicine of the University of Maastricht (1981-1990) and at the Faculty of Medicine of the Erasmus University in Rotterdam (1990-1995). In 1995 he was appointed Director of the University Institute of Pathology at the University Medical Center (CHUV) of Lausanne in Switzerland and Professor of Pathology at Faculty of Biology and Medicine of the University of Lausanne. He became Honorary Professor in 2009. He is invited professor at the School of Medicine of the Patan Academy of Health Sciences in Kathmandu (Nepal) and at the Medical University of Havana (Cuba).

His life-long interest has been to develop an approach to Pathology in which experimental studies are conducted in close association with daily diagnostic practice, now commonly called translational research. His own research (combining diagnostic and experimental pathology) focused on the biology of digestive tract cancer, notably Barret's esophagus and colorectal cancer, with a strong emphasis on the development of molecular diagnostics. Along this line, in the Institute of Pathology in Lausanne a Division of Experimental Pathology was created.

During his academic career Fred Bosman has deployed significant activities at administrative level. He was member of the Central Committee for the Registration of Medical Specialists in the Netherlands, President of the Dutch Society for Pathology, vice-dean of the Faculty of Medicine in Maastricht, Chairman of the Science Review Committee of the Faculty of Medicine in Rotterdam. He was President of the Society for Histochemistry, was President of the European Society of Pathology. He is member of the Scientific Advisory Board of several renowned Research Institutes, former Vice-President of Oncosuisse, the Swiss Organisation for the fight against cancer, former President of Biobank-Suisse. He is foreign correspondent of the Royal Netherlands Academy of Sciences. He was Associate-Dean of education in Lausanne, initiating profound educational reform in the Lausanne undergraduate medical curriculum. He is an Honorary Fellow of the Royal College of Pathologists (UK).

Scientific writing and editorial activities have also been part of Fred Bosman's activities. He was member of the Editorial Board of the Dutch Medical Journal (and president of its Society). He is member of the Editorial Board of 10 international journals in the fields of Pathology and Histochemistry (former Associate Editor of the Journal of Pathology and presently Editor in Chief of Virchows Archiv). For years he was one of the Editors of the Dutch textbook 'Oncology' and of the Dutch textbook 'Pathology'. He is Section Editor 'Gastro-Intestinal Pathology' for a new online Textbook of Pathology. He is Series-coeditor of the WHO Series 'Classification of Human Tumours', the international standard for tumour classification. He has written over 300 original publications (H-index 60).

Prof. Marc M. K. Mareel

Biosketch Prof. Marc M. K. Mareel

Prof. Marc Mareel studied medicine at the State University of Gent, where he graduated with great distinction in 1964. He obtained a PhD in Oncology from the same University in 1972 on a thesis entitled: Comparative study of neoplastic and nonneoplastic cells after transplantation in young chick blastoderms. His pioneering work in modelling tumour cell invasion in vitro earned him world fame. He was appointed Associate Professor in Gent in 1983 and in 1991 Professor of oncology and head of the Department of Radiotherapy & Nuclear Medicine, which he served until his retirement in 2003. In 2007 he was nominated Co-President of the Foundation against Cancer.

His main scientific activities have included

  • Gastrulation in the early bird blastoderm;
  • Transplantation of cancer cells into an early embryonic environment;
  • In vitro organ culture systems for cancer invasion;
  • Anti-invasive activities of microtubule inhibitors;
  • Role of oncogenes in cancer invasion;
  • The invasion-suppressor function of the E-cadherin/catenin complex;
  • Invasion of micro-organisms: parallels with cancer invasion;
  • The ΑE-catenin gene (CTNNA1): an invasion-suppressor gene in DNA mismatch repair-deficient colon cancer;
  • Regulation of cancer and non-cancer invasion and metastasis by host factors;
  • Effects of ionizing radiation on invasion and metastasis.

All through his scientific career prof. Mareel remained active as a clinician, in Radiotherapy, Nuclear Medicine, Radiotherapy-Oncology and Multidisciplinary Oncology.

Professor Mareel's publication list includes more than 350 scientific publications in peer-reviewed journals, 50 chapters in books and one book (h-index = 58). He continues working on effects of ionizing radiation on invasion and metastasis: biological interpretations of clinical observations.

Prof. Holger Moch

Biosketch Prof. Holger Moch

Prof. Holger Moch studied Medicine at the Faculty of Medicine of the Humboldt-University, Charité, Berlin, where he earned his MD degree in 1988. In the same year he earned a Doctorate in Medicine on experimental studies in oncology. In 1993 he was Board Anatomical Pathology. He obtained his 'Habilitation' (University Lecturer title) at the University Basel in 1998. In 2004 he earned a Certificate in Molecular Pathology. During his tenure as staff pathologist at the Institute for Pathology, University of Basel he spent a research fellowship in 1994 in the Division of Molecular Cytometry, Department of Laboratory Medicine, University of California San Francisco and was Visiting the Department of Pathology, Massachusetts General Hospital Boston. In 2001 he was appointed Associate Professor of Pathology, University Basel, and in 2004 Full Professor and Chair of Surgical Pathology, University Zürich, Switzerland. In 2010 he became Director of the Medical Division Pathology and Laboratory Medicine of the University Hospital Zurich.

Professor Moch is a member of the United States and Canadian Academy of Pathology, the German Society for Pathology (Executive Committee), the Swiss Society for Pathology (Executive Committee), the Cancer Network Zürich, the Editorial Board of various journals and Boards Member of several cancer research foundations. In 2007 he was elected as Member of the "German Academy of Sciences Leopoldina".

His primary research interests include among others Urinary tract cancer and Assay development in surgical pathology.

He is author of over 350 scientific publications (H-index 60).

Gerhard Christofori

Biosketch Prof. Gerhard Christofori

Gerhard Christofori (1957) studied Biology at the University of Heidelberg and obtained his Diploma in 1985 and his PhD in 1988 in the laboratory of Walter Keller at the German Cancer Research Center in Heidelberg and at the Biocenter of the University Basel on the biochemistry of 3' processing and polyadenylation of eukaryotic messenger RNA. He did postdoctoral training with Douglas Hanahan at the University of California San Francisco, USA, where he began to study the molecular mechanisms of multistage tumor development. In 1994 he became a group leader at the Institute of Molecular Pathology (IMP) in Vienna, Austria. Since 2001 he is Professor and Chair of Biochemistry within the Department of Biomedicine at the University of Basel.

His laboratory uses cultured cancer cell lines in vitro and refined transgenic mouse models of carcinogenesis in vivo to unravel the molecular mechanisms underlying malignant tumor progression and metastasis formation. One major focus in the laboratory is the transcriptional and epigenetic control of epithelial-mesenchymal transition (EMT) during tumor progression. Another focus is based on the observation that tumor malignancy is not only induced by changes within the tumor cells themselves but also by the tumor microenvironment.

He is author of more than 100 original research publications (H-index 49).

Prof. Ferdy Lejeune

Biosketch Prof. Ferdy Lejeune

Prof. Ferdy Lejeune graduated from the Free University of Brussels Medical School, Belgium, in 1964 and trained in Surgical Oncology at the Jules Bordet Institute, Cancer Centre of the same university. He spent two years fellowship at the Chester-Beatty Research Institute in London with Peter Alexander and Gordon Hamilton Fairley and delivered his PhD thesis in tumour immunology in Brussels in 1976. Since then, his special interest is melanoma biology, immunology and clinical management. He became Staff Member at the Department of Surgery of Bordet Institute and founded the Laboratory of Oncology and Experimental Surgery. From 1992 to 2004, he was Professor of Oncology at Lausanne University Medical School and Director of the Oncology Center and Affiliated Clinical Member of the Ludwig Institute for Cancer Research. In 1995, he won the Cancer Research Institute (CRI) Award for Distinguished Work in Tumor Immunology (New York), for his pioneer work on the use of TNF_ in isolated limb perfusion for melanoma and sarcoma. He is past president of the Melanoma Group and of the Chairman's Conference of the European Organization for Research and Treatment of Cancer (EORTC) and Editor in chief of Melanoma Research.

He is author of more than 200 original publications (H-index 55).